Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

437.15 +2.63 (+0.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
68 69 Next >
News headline image
US Stocks To Open On A Positive Note After A String Of Bad Mondays: Recent Dip Has 'Reached Its Low Point,' Says Technical Analyst ↗
U.S. stock futures rose on Monday following Friday's sharp fall as investors digest tariff updates and earnings reports. 
Via Benzinga
Topics World Trade
News headline image
Earnings Scheduled For February 10, 2025 ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
McDonald's, ON Semiconductor And 3 Stocks To Watch Heading Into Monday ↗
Stock futures up, focus on McDonald's, ON Semiconductor, VOXX, Rockwell Automation, Vertex Pharmaceuticals. 
Via Benzinga
News headline image
2 Biotech Stocks to Buy Hand Over Fist in February ↗
Via The Motley Fool
News headline image
Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. 
Via StockStory
News headline image
UnitedHealth, Vertex Pharmaceuticals, Axon Enterprise And A Major Energy Stock: CNBC's 'Final Trades' ↗
UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72. 
Via Benzinga
News headline image
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now? ↗
Via The Motley Fool
News headline image
Vertex Pharmaceuticals Unusual Options Activity ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (21 Ratings) ↗
 
Via Benzinga
News headline image
Is Vertex Pharmaceuticals Stock a Buy in 2025? ↗
Via The Motley Fool
News headline image
3 Magnificent Stocks to Buy and Hold Forever ↗
Via The Motley Fool
News headline image
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy? ↗
Via The Motley Fool
News headline image
What You Missed On Friday ↗
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? ↗
Via The Motley Fool
News headline image
Small- To Mid-Cap Biotech Trades Poised For Gains ↗
On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these... 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
FDA Approves First Non-Opioid Pain Pill, As Medical Marijuana Remains A Proven Alternative For Relief ↗
FDA approves non-opioid pain reliever, suzetrigine, by Vertex Pharmaceuticals to mitigate risks of opioids and provide patients with more options. 
Via Benzinga
Topics Cannabis
News headline image
What's going on in today's session: S&P500 movers ↗
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
News headline image
Top S&P500 movers in Friday's session ↗
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
Vertex Pharmaceuticals Stock Soars As Non-Opioid Pain Treatment Gets FDA Nod ↗
Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing acute pain. 
Via Talk Markets
Topics Stocks / Equities
News headline image
How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter ↗
The company won Food and Drug Administration approval for its non-opioid painkiller pill on Thursday. 
Via Investor's Business Daily
News headline image
Vertex Pharmaceuticals Shares Are Up Today: What's Going On? ↗
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen its position in both pain management and gene therapy. 
Via Benzinga
News headline image
Charter Communications Posts Upbeat Earnings, Joins Atlassian, SkyWest, Eastman Chemical, AbbVie And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Friday's pre-market session: top gainers and losers in the S&P500 index ↗
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
News headline image
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
From Vertex Pharmaceuticals
Via Business Wire
News headline image
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller ↗
The first-in-class drug had suffered a setback in December. 
Via Investor's Business Daily
News headline image
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
This Everest Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever. ↗
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.